You just read:

Mylan Invalidates Two of Teva's Copaxone® 40 mg/mL Patents Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding

News provided by

Mylan N.V.

24 Aug, 2016, 16:47 ET